CI

At a glance

ClinicalIndex Comparison Record
Phase 2Active· 53 enrolled / 53 target
Drug / intervention
Hydroxychloroquine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03032406
NCT03032406Phase 2ActiveUpdate Overdue (0.5/mo)Completion was 49mo ago
CompareCT.gov

CLEVER Pilot Trial: A Phase II Pilot Trial of HydroxyChLoroquine, EVErolimus or the Combination for Prevention of Recurrent Breast Cancer

Abramson Cancer Center at Penn Medicine·interventional·Posted Jan 26, 2017·Updated Jun 29, 2026

In Brief

A Phase 2 clinical trial evaluating Hydroxychloroquine and Everolimus for Breast Cancer Stage IIB. Active but no longer recruiting, targeting 53 participants across 1 site.

Signals

Enrollment appears stalled

Detailed Summary

To evaluate the feasibility of administering HCQ, EVE or the combination in patients who have completed primary therapy for breast cancer and harbor bone marrow disseminated tumor cells.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer Stage IIB
CountriesUnited States
Collaborators--

Timeline

Phase 2Active
20172018201920202021202220232024202520262027
First PostedJan 26, 2017
Enrollment StartJan 23, 2017
Primary CompletionMay 17, 2022
Study CompletionJan 1, 2027
TodayJul 2, 2026
Enrollment to primary: 5.3 yearsPosted 9.4 years ago

Arms & Interventions

HCQ alone (Arm A)experimental

Drug: Hydroxychloroquine
EVE alone (Arm B)experimental

Drug: Everolimus
combination HCQ and EVE (Arm C+D)experimental

Drug: HydroxychloroquineDrug: Everolimus

Interventions

Hydroxychloroquinedrug

Hydroxychloroquine

Everolimusdrug

Everolimus